相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Importing oncology trials from China: a bridge over troubled waters?
Harpreet Singh et al.
LANCET ONCOLOGY (2022)
Comparing development strategies for PD1/PDL1-based immunotherapies
Guanqiao Li et al.
NATURE REVIEWS DRUG DISCOVERY (2022)
The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives
Giorgio Patelli et al.
CANCER TREATMENT REVIEWS (2022)
FROM THE ANALYST'S COUCH Evolution of innovative drug R&D in China
Guanqiao Li et al.
NATURE REVIEWS DRUG DISCOVERY (2022)
Trends in innovative drug development in China
Xian Su et al.
NATURE REVIEWS DRUG DISCOVERY (2022)
Evolving drug regulatory landscape in China: A clinical pharmacology perspective
Weifeng Tang et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)
A Decade of FDA-Approved Drugs (2010-2019): Trends and Future Directions
Dean G. Brown et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
REGULATORY WATCH Characteristics of expedited programmes for cancer drug approval in China
Guanqiao Li et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Dynamics of life expectancy and life span equality
Jose Manuel Aburto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Peter Hillmen et al.
FUTURE ONCOLOGY (2020)
Launch Delay of New Drugs in China and Effect on Patients' Health
Xingyue Zhu et al.
CLINICAL THERAPEUTICS (2020)
Policy Recommendations to Promote Prescription Drug Competition: A Position Paper From the American College of Physicians
Hilary Daniel et al.
ANNALS OF INTERNAL MEDICINE (2020)
Simultaneous development of zanubrutinib in the USA and China
Guanqiao Li et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Challenges and Opportunities With Oncology Drug Development in China
Gaurav Bajaj et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
LBA62Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358
R W Naumann et al.
ANNALS OF ONCOLOGY (2019)
US Food and Drug Administration review of statistical analysis of patient-reported outcomes in lung cancer clinical trials approved between January, 2008, and December, 2017
Mallorie H. Fiero et al.
LANCET ONCOLOGY (2019)
Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration
Kuo Jiao et al.
JAMA NETWORK OPEN (2019)
Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada
Paul G Kluetz et al.
LANCET ONCOLOGY (2018)
Reforming China's drug regulatory system
Lili Xu et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Clinical trials and drug approvals continue to accelerate in China
Mai Wang
LANCET ONCOLOGY (2017)
China cracks down on fake data in drug trials
David Cyranoski
NATURE (2017)
The changing landscape of clinical trial and approval processes in China
Qing Zhou et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Chinese biopharma starts feeding the global pipeline
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2017)
REGULATORY WATCH Innovative drug availability in China
Liming Shao et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Patient-focused drug development programme takes first steps
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2013)
How Many Me-Too Drugs Is Too Many?
Joshua J. Gagne et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Rare diseases, orphan drugs and their regulation: questions and misconceptions
Erik Tambuyzer
NATURE REVIEWS DRUG DISCOVERY (2010)
Accelerating orphan drug development
Timothy R. Cote et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
分享论文
